CA2988930A1 - Bacteries modifiees en vue du traitement de maladies associees a l'hyperammoniemie - Google Patents

Bacteries modifiees en vue du traitement de maladies associees a l'hyperammoniemie Download PDF

Info

Publication number
CA2988930A1
CA2988930A1 CA2988930A CA2988930A CA2988930A1 CA 2988930 A1 CA2988930 A1 CA 2988930A1 CA 2988930 A CA2988930 A CA 2988930A CA 2988930 A CA2988930 A CA 2988930A CA 2988930 A1 CA2988930 A1 CA 2988930A1
Authority
CA
Canada
Prior art keywords
genetically engineered
gene
bacterium
promoter
engineered bacterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2988930A
Other languages
English (en)
Inventor
Dean Falb
Vincent M. Isabella
Jonathan W. Kotula
Paul F. Miller
Suman MACHINANI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synlogic Operating Co Inc
Original Assignee
Synlogic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/960,333 external-priority patent/US9487764B2/en
Priority claimed from PCT/US2016/020530 external-priority patent/WO2016141108A1/fr
Application filed by Synlogic Inc filed Critical Synlogic Inc
Publication of CA2988930A1 publication Critical patent/CA2988930A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/10—Citrulline; Arginine; Ornithine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/62—Carboxylic acid esters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/185—Escherichia
    • C12R2001/19—Escherichia coli

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

L'invention concerne des bactéries génétiquement modifiées, des compositions pharmaceutiques à base de celles-ci ainsi que des méthodes de modulation et de traitement de troubles associés à l'hyperammoniémie.
CA2988930A 2015-06-10 2016-05-25 Bacteries modifiees en vue du traitement de maladies associees a l'hyperammoniemie Abandoned CA2988930A1 (fr)

Applications Claiming Priority (31)

Application Number Priority Date Filing Date Title
US201562173706P 2015-06-10 2015-06-10
US201562173710P 2015-06-10 2015-06-10
US62/173,710 2015-06-10
US62/173,706 2015-06-10
US201562183935P 2015-06-24 2015-06-24
US62/183,935 2015-06-24
US201562184811P 2015-06-25 2015-06-25
US201562184770P 2015-06-25 2015-06-25
US62/184,770 2015-06-25
US62/184,811 2015-06-25
US201562248805P 2015-10-30 2015-10-30
US62/248,805 2015-10-30
US201562256041P 2015-11-16 2015-11-16
US201562256039P 2015-11-16 2015-11-16
US201562256048P 2015-11-16 2015-11-16
US62/256,039 2015-11-16
US62/256,041 2015-11-16
US62/256,048 2015-11-16
US201562263329P 2015-12-04 2015-12-04
US62/263,329 2015-12-04
US14/960,333 US9487764B2 (en) 2014-12-05 2015-12-04 Bacteria engineered to treat diseases associated with hyperammonemia
US14/960,333 2015-12-04
US201662277654P 2016-01-12 2016-01-12
US62/277,654 2016-01-12
US201662291468P 2016-02-04 2016-02-04
US62/291,468 2016-02-04
US201662293749P 2016-02-10 2016-02-10
US62/293,749 2016-02-10
USPCT/US16/020530 2016-03-02
PCT/US2016/020530 WO2016141108A1 (fr) 2015-03-02 2016-03-02 Bactéries modifiées pour traiter des maladies pour lesquelles une diminution de l'inflammation intestinale et/ou une plus grande imperméabilité de la muqueuse intestinale s'avèrent bénéfiques
PCT/US2016/034200 WO2016200614A2 (fr) 2015-06-10 2016-05-25 Bactéries modifiées en vue du traitement de maladies associées à l'hyperammoniémie

Publications (1)

Publication Number Publication Date
CA2988930A1 true CA2988930A1 (fr) 2016-12-15

Family

ID=57504262

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2988930A Abandoned CA2988930A1 (fr) 2015-06-10 2016-05-25 Bacteries modifiees en vue du traitement de maladies associees a l'hyperammoniemie

Country Status (5)

Country Link
EP (1) EP3307879A2 (fr)
JP (2) JP6817966B2 (fr)
AU (1) AU2016274311A1 (fr)
CA (1) CA2988930A1 (fr)
WO (1) WO2016200614A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017136795A1 (fr) 2016-02-04 2017-08-10 Synlogic, Inc. Bactéries modifiées pour traiter des maladies associées au metabolisme du tryptophane
AU2018272294B2 (en) * 2017-05-24 2024-05-23 Thoeris Gmbh Use of glutamine synthetase for treating hyperammonemia
MX2020005875A (es) * 2017-12-05 2020-10-08 Bioplx Inc Métodos y composiciones para prevenir la infección microbiana.
CN110446259B (zh) * 2018-05-04 2022-04-15 大唐移动通信设备有限公司 一种寻呼机会的位置确定方法及通信设备
US20220257732A1 (en) 2019-04-29 2022-08-18 Synlogic Operating Company, Inc. Enumeration of genetically engineered microorganisms by live cell counting techniques
WO2020239882A1 (fr) 2019-05-30 2020-12-03 Recordati Industria Chimica E Farmaceutica S.P.A. Formulation pharmaceutique pour l'acide carglumique
CA3142608A1 (fr) 2019-06-04 2020-12-10 Cocoon Biotech Inc. Produits a base de soie, formulations et procedes d'utilisation
CN115279888B (zh) * 2019-11-29 2024-04-02 株式会社Jinis 具有降低血氨数值效能的菌株及包含其的用于保护神经细胞的组合物
US20240110191A1 (en) 2020-12-02 2024-04-04 Synlogic Operating Company, Inc. Engineered microorganisms
JP7260841B2 (ja) 2021-03-31 2023-04-19 日本製鉄株式会社 無方向性電磁鋼板の打ち抜き方法および無方向性電磁鋼板の打ち抜き用金型

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3083315B2 (ja) * 1990-10-29 2000-09-04 株式会社ヤクルト本社 血中アンモニア低下剤
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
IT1290679B1 (it) * 1997-02-14 1998-12-10 Alfa Wassermann Spa Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
EP1135461A4 (fr) 1998-12-02 2003-03-26 Univ Boston Reseaux de genes destines a controler l'expression genetique
EP1034787A1 (fr) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Souches de lactobacillus capables de prévenir la diarrhée causée des bactéries pathogènes
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
WO2009123029A1 (fr) * 2008-03-31 2009-10-08 株式会社 大塚製薬工場 Régulateur de niveau d’ammoniac dans le sang
CA2926466C (fr) * 2013-10-03 2021-11-16 Frederic Bushman Compositions comprenant un microbiome defini et procedes d'utilisation de ces compositions

Also Published As

Publication number Publication date
JP2018523978A (ja) 2018-08-30
WO2016200614A2 (fr) 2016-12-15
JP6817966B2 (ja) 2021-01-20
WO2016200614A3 (fr) 2017-01-12
JP2021061846A (ja) 2021-04-22
AU2016274311A1 (en) 2018-01-18
EP3307879A2 (fr) 2018-04-18

Similar Documents

Publication Publication Date Title
US11845964B2 (en) Bacteria engineered to treat diseases associated with hyperammonemia
US20200246394A1 (en) Bacteria Engineered to Reduce Hyperphenylalaninemia
AU2015357549B2 (en) Bacteria engineered to treat diseases associated with hyperammonemia
US20170232043A1 (en) Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid
CA2988930A1 (fr) Bacteries modifiees en vue du traitement de maladies associees a l'hyperammoniemie
US20240076645A1 (en) Bacteria engineered to reduce hyperphenylalaninemia
WO2017139697A1 (fr) Bactéries modifiées en vue du traitement de maladies associées à l'hyperammoniémie
EP3227440B1 (fr) Bactéries modifiées pour traiter des maladies associées à l'hyperammoniémie
AU2021220882A1 (en) Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof
US20220168362A1 (en) Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid
WO2017023818A1 (fr) Bactéries modifiées pour traiter les troubles impliquant le catabolisme du propionate

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210525

EEER Examination request

Effective date: 20210525

EEER Examination request

Effective date: 20210525

EEER Examination request

Effective date: 20210525

FZDE Discontinued

Effective date: 20230927